Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between gemcitabine and mitomycin-C in vitro.

T T Aung1, M A Davis, W D Ensminger

  • 1Department of Internal Medicine, University of Michigan, Ann Arbor, USA.

Cancer Chemotherapy and Pharmacology
|January 27, 2000
PubMed
Summary

Concurrent use of gemcitabine (dFdCyd) and mitomycin-C (MMC) showed significant synergy in colon cancer cells. This combination may improve cancer treatment outcomes when administered together.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study.

The journal of prevention of Alzheimer's disease·2024
Same author

US Adults' Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging.

The journal of prevention of Alzheimer's disease·2023
Same author

Response to Kibe Y et al. "Methodological concerns for investigating the effects of midtreatment break of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC)".

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2020
Same author

A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2019
Same author

Evidence for a Pythium sp. as a Chronic Yield Reducer in a Continuous Grain Sorghum Field.

Plant disease·2019
Same author

Calf care personnel on dairy farms and their educational opportunities.

Journal of dairy science·2019

Area of Science:

  • Oncology
  • Molecular Pharmacology
  • Cancer Biology

Background:

  • Gemcitabine (2',2'-difluorodeoxycytidine; dFdCyd) and mitomycin-C (MMC) are established chemotherapeutic agents for solid tumors.
  • Gemcitabine inhibits DNA replication and repair, and exhibits radiosensitizing properties, making it suitable for combination therapies.
  • The hypothesis is that gemcitabine may enhance mitomycin-C efficacy by inhibiting DNA repair of mitomycin-C adducts.

Purpose of the Study:

  • To investigate the synergistic potential of combining gemcitabine and mitomycin-C in HT29 human colon carcinoma cells.
  • To evaluate the impact of different drug concentrations and administration schedules on cell survival.
  • To determine the interaction index (combination index, CI) to quantify synergistic, additive, or antagonistic effects.

Main Methods:

Related Experiment Videos

  • HT29 human colon carcinoma cells were treated with varying concentrations and schedules of gemcitabine and mitomycin-C.
  • Clonogenic survival assays were performed to assess cell viability post-treatment.
  • Median effect analysis was employed to calculate the combination index (CI) for drug interactions.

Main Results:

  • Concurrent administration of gemcitabine and mitomycin-C resulted in marked synergy, with a combination index (CI) between 0.5 and 0.7.
  • Sequential treatment with these drugs demonstrated only additive effects, not synergistic.
  • The findings indicate a strong synergistic interaction when gemcitabine and mitomycin-C are given simultaneously.

Conclusions:

  • Concurrent administration of gemcitabine and mitomycin-C exhibits significant synergistic effects in HT29 colon cancer cells.
  • Gemcitabine's ability to inhibit DNA repair may potentiate the DNA-damaging effects of mitomycin-C.
  • This combination, when scheduled appropriately, holds promise for enhancing the treatment of mitomycin-C-sensitive malignancies.